ROIV: Mosliciguat's breakthrough data and brepocitinib's strong launch drive broad pipeline momentum
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting broad indication expansion and rapid phase III initiation. Brepocitinib's DM launch is progressing steadily, with strong physician interest and significant market potential, while NIU and FcRN programs offer major upcoming c…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.